Evaluation of important human CYP450 isoforms and P-glycoprotein phenotype changes and genotype in type 2 diabetic patients, before and after treatment, by using Geneva cocktail Article Swipe
Navid Neyshaburinezhad
,
Nooshin Shirzad
,
Mohammad Reza Rouini
,
Soha Namazi
,
Mohammadreza Khoshayand
,
Alireza Esteghamati
,
Manooshehr Nakhjavani
,
Hengameh Ghasim
,
Youssef Daali
,
Yalda H. Ardakani
·
YOU?
·
· 2022
· Open Access
·
· DOI: https://doi.org/10.22541/au.167025244.46141774/v1
YOU?
·
· 2022
· Open Access
·
· DOI: https://doi.org/10.22541/au.167025244.46141774/v1
The present study evaluates the influence of type 2 diabetes (T2D) on important CYP450 isoforms and P-glycoprotein (P-gp) transporter activities before and 3 months after intensifying treatment regimen of 40 patients. Results have been compared with 21 non-T2D healthy participants (control group). CYPs and P-gp activities were assessed after administration of Geneva cocktail. Mean metabolic ratios (MR) for CYP2B6 (1.81±0.93 vs. 2.68±0.87), CYP2C19 (0.420 ± 0.360 vs. 0.687 ± 0.558), and CYP3A4/5 (0.487 ± 0.226 vs. 0.633 ± 0.254) significantly decreased in T2D subjects compared to control group (p<0.05). CYP2C9 (0.089±0.037 vs. 0.069±0.017) activities slightly increased in diabetic subjects and no difference was observed for CYP1A2 (0.154±0.085 vs. 0.136±0.065), CYP2D6 (1.17 ± 0.56 vs. 1.24 ± 0.83) and P-gp activities in comparison with control group. Three months after intensifying treatment regimen, MRs of CYP2C9 (0.080 ± 0.030) and CYP3A4/5 (0.592 ± 0.268) have shown a significant improvement and were not statistically different compared to control group (P>0.05). Several covariables such as inflammatory markers (IL-1β and IL-6), genotypes, diabetes- and demographic-related factors were considered in our analyses. Our results indicate that low chronic inflammatory status associated with T2D modulates CYP450 activities in an isoform specific manner.
Related Topics
Concepts
CYP2C19
Regimen
Internal medicine
CYP3A4
CYP1A2
Type 2 diabetes
CYP2B6
CYP2D6
Gene isoform
Genotype
Diabetes mellitus
Medicine
CYP2C9
Endocrinology
Pharmacology
Gastroenterology
Cytochrome P450
Biology
Gene
Metabolism
Biochemistry
Metadata
- Type
- preprint
- Language
- en
- Landing Page
- https://doi.org/10.22541/au.167025244.46141774/v1
- https://www.authorea.com/doi/pdf/10.22541/au.167025244.46141774
- OA Status
- gold
- Cited By
- 1
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4310728744
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4310728744Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.22541/au.167025244.46141774/v1Digital Object Identifier
- Title
-
Evaluation of important human CYP450 isoforms and P-glycoprotein phenotype changes and genotype in type 2 diabetic patients, before and after treatment, by using Geneva cocktailWork title
- Type
-
preprintOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2022Year of publication
- Publication date
-
2022-12-05Full publication date if available
- Authors
-
Navid Neyshaburinezhad, Nooshin Shirzad, Mohammad Reza Rouini, Soha Namazi, Mohammadreza Khoshayand, Alireza Esteghamati, Manooshehr Nakhjavani, Hengameh Ghasim, Youssef Daali, Yalda H. ArdakaniList of authors in order
- Landing page
-
https://doi.org/10.22541/au.167025244.46141774/v1Publisher landing page
- PDF URL
-
https://www.authorea.com/doi/pdf/10.22541/au.167025244.46141774Direct link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://www.authorea.com/doi/pdf/10.22541/au.167025244.46141774Direct OA link when available
- Concepts
-
CYP2C19, Regimen, Internal medicine, CYP3A4, CYP1A2, Type 2 diabetes, CYP2B6, CYP2D6, Gene isoform, Genotype, Diabetes mellitus, Medicine, CYP2C9, Endocrinology, Pharmacology, Gastroenterology, Cytochrome P450, Biology, Gene, Metabolism, BiochemistryTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
1Total citation count in OpenAlex
- Citations by year (recent)
-
2023: 1Per-year citation counts (last 5 years)
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4310728744 |
|---|---|
| doi | https://doi.org/10.22541/au.167025244.46141774/v1 |
| ids.doi | https://doi.org/10.22541/au.167025244.46141774/v1 |
| ids.openalex | https://openalex.org/W4310728744 |
| fwci | 0.23295226 |
| type | preprint |
| title | Evaluation of important human CYP450 isoforms and P-glycoprotein phenotype changes and genotype in type 2 diabetic patients, before and after treatment, by using Geneva cocktail |
| biblio.issue | |
| biblio.volume | |
| biblio.last_page | |
| biblio.first_page | |
| topics[0].id | https://openalex.org/T10375 |
| topics[0].field.id | https://openalex.org/fields/30 |
| topics[0].field.display_name | Pharmacology, Toxicology and Pharmaceutics |
| topics[0].score | 0.9997000098228455 |
| topics[0].domain.id | https://openalex.org/domains/1 |
| topics[0].domain.display_name | Life Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/3004 |
| topics[0].subfield.display_name | Pharmacology |
| topics[0].display_name | Pharmacogenetics and Drug Metabolism |
| topics[1].id | https://openalex.org/T10570 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9972000122070312 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2730 |
| topics[1].subfield.display_name | Oncology |
| topics[1].display_name | Drug Transport and Resistance Mechanisms |
| topics[2].id | https://openalex.org/T12910 |
| topics[2].field.id | https://openalex.org/fields/13 |
| topics[2].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[2].score | 0.995199978351593 |
| topics[2].domain.id | https://openalex.org/domains/1 |
| topics[2].domain.display_name | Life Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/1303 |
| topics[2].subfield.display_name | Biochemistry |
| topics[2].display_name | Eicosanoids and Hypertension Pharmacology |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C140840227 |
| concepts[0].level | 4 |
| concepts[0].score | 0.6919158697128296 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q3737532 |
| concepts[0].display_name | CYP2C19 |
| concepts[1].id | https://openalex.org/C2781413609 |
| concepts[1].level | 2 |
| concepts[1].score | 0.6201232075691223 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q7308373 |
| concepts[1].display_name | Regimen |
| concepts[2].id | https://openalex.org/C126322002 |
| concepts[2].level | 1 |
| concepts[2].score | 0.6166827082633972 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[2].display_name | Internal medicine |
| concepts[3].id | https://openalex.org/C109650736 |
| concepts[3].level | 4 |
| concepts[3].score | 0.6148019433021545 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q424440 |
| concepts[3].display_name | CYP3A4 |
| concepts[4].id | https://openalex.org/C86745063 |
| concepts[4].level | 4 |
| concepts[4].score | 0.593214213848114 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q3737406 |
| concepts[4].display_name | CYP1A2 |
| concepts[5].id | https://openalex.org/C2777180221 |
| concepts[5].level | 3 |
| concepts[5].score | 0.5822597742080688 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q3025883 |
| concepts[5].display_name | Type 2 diabetes |
| concepts[6].id | https://openalex.org/C50605568 |
| concepts[6].level | 5 |
| concepts[6].score | 0.566586971282959 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q14912267 |
| concepts[6].display_name | CYP2B6 |
| concepts[7].id | https://openalex.org/C33664856 |
| concepts[7].level | 4 |
| concepts[7].score | 0.5565993785858154 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q3271142 |
| concepts[7].display_name | CYP2D6 |
| concepts[8].id | https://openalex.org/C53345823 |
| concepts[8].level | 3 |
| concepts[8].score | 0.5277902483940125 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q5531554 |
| concepts[8].display_name | Gene isoform |
| concepts[9].id | https://openalex.org/C135763542 |
| concepts[9].level | 3 |
| concepts[9].score | 0.5191516280174255 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q106016 |
| concepts[9].display_name | Genotype |
| concepts[10].id | https://openalex.org/C555293320 |
| concepts[10].level | 2 |
| concepts[10].score | 0.5085676908493042 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q12206 |
| concepts[10].display_name | Diabetes mellitus |
| concepts[11].id | https://openalex.org/C71924100 |
| concepts[11].level | 0 |
| concepts[11].score | 0.5010268688201904 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[11].display_name | Medicine |
| concepts[12].id | https://openalex.org/C3946865 |
| concepts[12].level | 4 |
| concepts[12].score | 0.4730735719203949 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q5014962 |
| concepts[12].display_name | CYP2C9 |
| concepts[13].id | https://openalex.org/C134018914 |
| concepts[13].level | 1 |
| concepts[13].score | 0.46867260336875916 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q162606 |
| concepts[13].display_name | Endocrinology |
| concepts[14].id | https://openalex.org/C98274493 |
| concepts[14].level | 1 |
| concepts[14].score | 0.4179666340351105 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q128406 |
| concepts[14].display_name | Pharmacology |
| concepts[15].id | https://openalex.org/C90924648 |
| concepts[15].level | 1 |
| concepts[15].score | 0.3682348430156708 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q120569 |
| concepts[15].display_name | Gastroenterology |
| concepts[16].id | https://openalex.org/C526171541 |
| concepts[16].level | 3 |
| concepts[16].score | 0.337049663066864 |
| concepts[16].wikidata | https://www.wikidata.org/wiki/Q407693 |
| concepts[16].display_name | Cytochrome P450 |
| concepts[17].id | https://openalex.org/C86803240 |
| concepts[17].level | 0 |
| concepts[17].score | 0.2689554691314697 |
| concepts[17].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[17].display_name | Biology |
| concepts[18].id | https://openalex.org/C104317684 |
| concepts[18].level | 2 |
| concepts[18].score | 0.14927250146865845 |
| concepts[18].wikidata | https://www.wikidata.org/wiki/Q7187 |
| concepts[18].display_name | Gene |
| concepts[19].id | https://openalex.org/C62231903 |
| concepts[19].level | 2 |
| concepts[19].score | 0.12997829914093018 |
| concepts[19].wikidata | https://www.wikidata.org/wiki/Q1057 |
| concepts[19].display_name | Metabolism |
| concepts[20].id | https://openalex.org/C55493867 |
| concepts[20].level | 1 |
| concepts[20].score | 0.10472831130027771 |
| concepts[20].wikidata | https://www.wikidata.org/wiki/Q7094 |
| concepts[20].display_name | Biochemistry |
| keywords[0].id | https://openalex.org/keywords/cyp2c19 |
| keywords[0].score | 0.6919158697128296 |
| keywords[0].display_name | CYP2C19 |
| keywords[1].id | https://openalex.org/keywords/regimen |
| keywords[1].score | 0.6201232075691223 |
| keywords[1].display_name | Regimen |
| keywords[2].id | https://openalex.org/keywords/internal-medicine |
| keywords[2].score | 0.6166827082633972 |
| keywords[2].display_name | Internal medicine |
| keywords[3].id | https://openalex.org/keywords/cyp3a4 |
| keywords[3].score | 0.6148019433021545 |
| keywords[3].display_name | CYP3A4 |
| keywords[4].id | https://openalex.org/keywords/cyp1a2 |
| keywords[4].score | 0.593214213848114 |
| keywords[4].display_name | CYP1A2 |
| keywords[5].id | https://openalex.org/keywords/type-2-diabetes |
| keywords[5].score | 0.5822597742080688 |
| keywords[5].display_name | Type 2 diabetes |
| keywords[6].id | https://openalex.org/keywords/cyp2b6 |
| keywords[6].score | 0.566586971282959 |
| keywords[6].display_name | CYP2B6 |
| keywords[7].id | https://openalex.org/keywords/cyp2d6 |
| keywords[7].score | 0.5565993785858154 |
| keywords[7].display_name | CYP2D6 |
| keywords[8].id | https://openalex.org/keywords/gene-isoform |
| keywords[8].score | 0.5277902483940125 |
| keywords[8].display_name | Gene isoform |
| keywords[9].id | https://openalex.org/keywords/genotype |
| keywords[9].score | 0.5191516280174255 |
| keywords[9].display_name | Genotype |
| keywords[10].id | https://openalex.org/keywords/diabetes-mellitus |
| keywords[10].score | 0.5085676908493042 |
| keywords[10].display_name | Diabetes mellitus |
| keywords[11].id | https://openalex.org/keywords/medicine |
| keywords[11].score | 0.5010268688201904 |
| keywords[11].display_name | Medicine |
| keywords[12].id | https://openalex.org/keywords/cyp2c9 |
| keywords[12].score | 0.4730735719203949 |
| keywords[12].display_name | CYP2C9 |
| keywords[13].id | https://openalex.org/keywords/endocrinology |
| keywords[13].score | 0.46867260336875916 |
| keywords[13].display_name | Endocrinology |
| keywords[14].id | https://openalex.org/keywords/pharmacology |
| keywords[14].score | 0.4179666340351105 |
| keywords[14].display_name | Pharmacology |
| keywords[15].id | https://openalex.org/keywords/gastroenterology |
| keywords[15].score | 0.3682348430156708 |
| keywords[15].display_name | Gastroenterology |
| keywords[16].id | https://openalex.org/keywords/cytochrome-p450 |
| keywords[16].score | 0.337049663066864 |
| keywords[16].display_name | Cytochrome P450 |
| keywords[17].id | https://openalex.org/keywords/biology |
| keywords[17].score | 0.2689554691314697 |
| keywords[17].display_name | Biology |
| keywords[18].id | https://openalex.org/keywords/gene |
| keywords[18].score | 0.14927250146865845 |
| keywords[18].display_name | Gene |
| keywords[19].id | https://openalex.org/keywords/metabolism |
| keywords[19].score | 0.12997829914093018 |
| keywords[19].display_name | Metabolism |
| keywords[20].id | https://openalex.org/keywords/biochemistry |
| keywords[20].score | 0.10472831130027771 |
| keywords[20].display_name | Biochemistry |
| language | en |
| locations[0].id | doi:10.22541/au.167025244.46141774/v1 |
| locations[0].is_oa | True |
| locations[0].source | |
| locations[0].license | |
| locations[0].pdf_url | https://www.authorea.com/doi/pdf/10.22541/au.167025244.46141774 |
| locations[0].version | acceptedVersion |
| locations[0].raw_type | posted-content |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | False |
| locations[0].raw_source_name | |
| locations[0].landing_page_url | https://doi.org/10.22541/au.167025244.46141774/v1 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5003493461 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-6651-6988 |
| authorships[0].author.display_name | Navid Neyshaburinezhad |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Navid Neyshaburinezhad |
| authorships[0].is_corresponding | False |
| authorships[1].author.id | https://openalex.org/A5103736172 |
| authorships[1].author.orcid | |
| authorships[1].author.display_name | Nooshin Shirzad |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Nooshin Shirzad |
| authorships[1].is_corresponding | False |
| authorships[2].author.id | https://openalex.org/A5036971214 |
| authorships[2].author.orcid | https://orcid.org/0000-0003-0412-8581 |
| authorships[2].author.display_name | Mohammad Reza Rouini |
| authorships[2].countries | IR |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I70640408 |
| authorships[2].affiliations[0].raw_affiliation_string | Tehran University of Medical Sciences School of Pharmacy |
| authorships[2].institutions[0].id | https://openalex.org/I70640408 |
| authorships[2].institutions[0].ror | https://ror.org/01c4pz451 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I70640408 |
| authorships[2].institutions[0].country_code | IR |
| authorships[2].institutions[0].display_name | Tehran University of Medical Sciences |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Mohammadreza Rouini |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Tehran University of Medical Sciences School of Pharmacy |
| authorships[3].author.id | https://openalex.org/A5032331674 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-6150-1648 |
| authorships[3].author.display_name | Soha Namazi |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Soha Namazi |
| authorships[3].is_corresponding | False |
| authorships[4].author.id | https://openalex.org/A5018836192 |
| authorships[4].author.orcid | |
| authorships[4].author.display_name | Mohammadreza Khoshayand |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Mohammadreza Khoshayand |
| authorships[4].is_corresponding | False |
| authorships[5].author.id | https://openalex.org/A5089768281 |
| authorships[5].author.orcid | https://orcid.org/0000-0001-5114-3982 |
| authorships[5].author.display_name | Alireza Esteghamati |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Alireza Esteghamati |
| authorships[5].is_corresponding | False |
| authorships[6].author.id | https://openalex.org/A5039434014 |
| authorships[6].author.orcid | |
| authorships[6].author.display_name | Manooshehr Nakhjavani |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Manooshehr Nakhjavani |
| authorships[6].is_corresponding | False |
| authorships[7].author.id | https://openalex.org/A5022561153 |
| authorships[7].author.orcid | |
| authorships[7].author.display_name | Hengameh Ghasim |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Hengameh Ghasim |
| authorships[7].is_corresponding | False |
| authorships[8].author.id | https://openalex.org/A5042744097 |
| authorships[8].author.orcid | https://orcid.org/0000-0002-8391-9383 |
| authorships[8].author.display_name | Youssef Daali |
| authorships[8].countries | CH |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I114457229 |
| authorships[8].affiliations[0].raw_affiliation_string | University of Geneva Faculty of Medicine |
| authorships[8].institutions[0].id | https://openalex.org/I114457229 |
| authorships[8].institutions[0].ror | https://ror.org/01swzsf04 |
| authorships[8].institutions[0].type | education |
| authorships[8].institutions[0].lineage | https://openalex.org/I114457229 |
| authorships[8].institutions[0].country_code | CH |
| authorships[8].institutions[0].display_name | University of Geneva |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Youssef Daali |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | University of Geneva Faculty of Medicine |
| authorships[9].author.id | https://openalex.org/A5011798315 |
| authorships[9].author.orcid | https://orcid.org/0000-0003-3719-6732 |
| authorships[9].author.display_name | Yalda H. Ardakani |
| authorships[9].countries | IR |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I70640408 |
| authorships[9].affiliations[0].raw_affiliation_string | Tehran University of Medical Sciences School of Pharmacy |
| authorships[9].institutions[0].id | https://openalex.org/I70640408 |
| authorships[9].institutions[0].ror | https://ror.org/01c4pz451 |
| authorships[9].institutions[0].type | education |
| authorships[9].institutions[0].lineage | https://openalex.org/I70640408 |
| authorships[9].institutions[0].country_code | IR |
| authorships[9].institutions[0].display_name | Tehran University of Medical Sciences |
| authorships[9].author_position | last |
| authorships[9].raw_author_name | Yalda H. Ardakani |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | Tehran University of Medical Sciences School of Pharmacy |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.authorea.com/doi/pdf/10.22541/au.167025244.46141774 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Evaluation of important human CYP450 isoforms and P-glycoprotein phenotype changes and genotype in type 2 diabetic patients, before and after treatment, by using Geneva cocktail |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10375 |
| primary_topic.field.id | https://openalex.org/fields/30 |
| primary_topic.field.display_name | Pharmacology, Toxicology and Pharmaceutics |
| primary_topic.score | 0.9997000098228455 |
| primary_topic.domain.id | https://openalex.org/domains/1 |
| primary_topic.domain.display_name | Life Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/3004 |
| primary_topic.subfield.display_name | Pharmacology |
| primary_topic.display_name | Pharmacogenetics and Drug Metabolism |
| related_works | https://openalex.org/W2035465414, https://openalex.org/W2277368739, https://openalex.org/W2033644570, https://openalex.org/W2039860301, https://openalex.org/W3009539525, https://openalex.org/W2118451906, https://openalex.org/W390133505, https://openalex.org/W4404504738, https://openalex.org/W4396841774, https://openalex.org/W2068780263 |
| cited_by_count | 1 |
| counts_by_year[0].year | 2023 |
| counts_by_year[0].cited_by_count | 1 |
| locations_count | 1 |
| best_oa_location.id | doi:10.22541/au.167025244.46141774/v1 |
| best_oa_location.is_oa | True |
| best_oa_location.source | |
| best_oa_location.license | |
| best_oa_location.pdf_url | https://www.authorea.com/doi/pdf/10.22541/au.167025244.46141774 |
| best_oa_location.version | acceptedVersion |
| best_oa_location.raw_type | posted-content |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | False |
| best_oa_location.raw_source_name | |
| best_oa_location.landing_page_url | https://doi.org/10.22541/au.167025244.46141774/v1 |
| primary_location.id | doi:10.22541/au.167025244.46141774/v1 |
| primary_location.is_oa | True |
| primary_location.source | |
| primary_location.license | |
| primary_location.pdf_url | https://www.authorea.com/doi/pdf/10.22541/au.167025244.46141774 |
| primary_location.version | acceptedVersion |
| primary_location.raw_type | posted-content |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | False |
| primary_location.raw_source_name | |
| primary_location.landing_page_url | https://doi.org/10.22541/au.167025244.46141774/v1 |
| publication_date | 2022-12-05 |
| publication_year | 2022 |
| referenced_works_count | 0 |
| abstract_inverted_index.2 | 8 |
| abstract_inverted_index.3 | 22 |
| abstract_inverted_index.a | 144 |
| abstract_inverted_index.21 | 36 |
| abstract_inverted_index.40 | 29 |
| abstract_inverted_index.an | 191 |
| abstract_inverted_index.as | 160 |
| abstract_inverted_index.in | 81, 96, 120, 173, 190 |
| abstract_inverted_index.no | 100 |
| abstract_inverted_index.of | 6, 28, 50, 132 |
| abstract_inverted_index.on | 11 |
| abstract_inverted_index.to | 85, 153 |
| abstract_inverted_index.± | 64, 68, 73, 77, 111, 115, 135, 140 |
| abstract_inverted_index.MRs | 131 |
| abstract_inverted_index.Our | 176 |
| abstract_inverted_index.T2D | 82, 186 |
| abstract_inverted_index.The | 0 |
| abstract_inverted_index.and | 15, 21, 43, 70, 99, 117, 137, 147, 164, 168 |
| abstract_inverted_index.for | 57, 104 |
| abstract_inverted_index.low | 180 |
| abstract_inverted_index.not | 149 |
| abstract_inverted_index.our | 174 |
| abstract_inverted_index.the | 4 |
| abstract_inverted_index.vs. | 60, 66, 75, 91, 107, 113 |
| abstract_inverted_index.was | 102 |
| abstract_inverted_index.(MR) | 56 |
| abstract_inverted_index.0.56 | 112 |
| abstract_inverted_index.1.24 | 114 |
| abstract_inverted_index.CYPs | 42 |
| abstract_inverted_index.Mean | 53 |
| abstract_inverted_index.P-gp | 44, 118 |
| abstract_inverted_index.been | 33 |
| abstract_inverted_index.have | 32, 142 |
| abstract_inverted_index.such | 159 |
| abstract_inverted_index.that | 179 |
| abstract_inverted_index.type | 7 |
| abstract_inverted_index.were | 46, 148, 171 |
| abstract_inverted_index.with | 35, 122, 185 |
| abstract_inverted_index.(1.17 | 110 |
| abstract_inverted_index.(T2D) | 10 |
| abstract_inverted_index.0.226 | 74 |
| abstract_inverted_index.0.360 | 65 |
| abstract_inverted_index.0.633 | 76 |
| abstract_inverted_index.0.687 | 67 |
| abstract_inverted_index.0.83) | 116 |
| abstract_inverted_index.Three | 125 |
| abstract_inverted_index.after | 24, 48, 127 |
| abstract_inverted_index.group | 87, 155 |
| abstract_inverted_index.shown | 143 |
| abstract_inverted_index.study | 2 |
| abstract_inverted_index.(0.080 | 134 |
| abstract_inverted_index.(0.420 | 63 |
| abstract_inverted_index.(0.487 | 72 |
| abstract_inverted_index.(0.592 | 139 |
| abstract_inverted_index.(P-gp) | 17 |
| abstract_inverted_index.0.030) | 136 |
| abstract_inverted_index.0.254) | 78 |
| abstract_inverted_index.0.268) | 141 |
| abstract_inverted_index.CYP1A2 | 105 |
| abstract_inverted_index.CYP2B6 | 58 |
| abstract_inverted_index.CYP2C9 | 89, 133 |
| abstract_inverted_index.CYP2D6 | 109 |
| abstract_inverted_index.CYP450 | 13, 188 |
| abstract_inverted_index.Geneva | 51 |
| abstract_inverted_index.IL-6), | 165 |
| abstract_inverted_index.before | 20 |
| abstract_inverted_index.group. | 124 |
| abstract_inverted_index.months | 23, 126 |
| abstract_inverted_index.ratios | 55 |
| abstract_inverted_index.status | 183 |
| abstract_inverted_index.(IL-1β | 163 |
| abstract_inverted_index.0.558), | 69 |
| abstract_inverted_index.CYP2C19 | 62 |
| abstract_inverted_index.Results | 31 |
| abstract_inverted_index.Several | 157 |
| abstract_inverted_index.chronic | 181 |
| abstract_inverted_index.control | 86, 123, 154 |
| abstract_inverted_index.factors | 170 |
| abstract_inverted_index.group). | 41 |
| abstract_inverted_index.healthy | 38 |
| abstract_inverted_index.isoform | 192 |
| abstract_inverted_index.manner. | 194 |
| abstract_inverted_index.markers | 162 |
| abstract_inverted_index.non-T2D | 37 |
| abstract_inverted_index.present | 1 |
| abstract_inverted_index.regimen | 27 |
| abstract_inverted_index.results | 177 |
| abstract_inverted_index.(control | 40 |
| abstract_inverted_index.CYP3A4/5 | 71, 138 |
| abstract_inverted_index.assessed | 47 |
| abstract_inverted_index.compared | 34, 84, 152 |
| abstract_inverted_index.diabetes | 9 |
| abstract_inverted_index.diabetic | 97 |
| abstract_inverted_index.indicate | 178 |
| abstract_inverted_index.isoforms | 14 |
| abstract_inverted_index.observed | 103 |
| abstract_inverted_index.regimen, | 130 |
| abstract_inverted_index.slightly | 94 |
| abstract_inverted_index.specific | 193 |
| abstract_inverted_index.subjects | 83, 98 |
| abstract_inverted_index.analyses. | 175 |
| abstract_inverted_index.cocktail. | 52 |
| abstract_inverted_index.decreased | 80 |
| abstract_inverted_index.diabetes- | 167 |
| abstract_inverted_index.different | 151 |
| abstract_inverted_index.evaluates | 3 |
| abstract_inverted_index.important | 12 |
| abstract_inverted_index.increased | 95 |
| abstract_inverted_index.influence | 5 |
| abstract_inverted_index.metabolic | 54 |
| abstract_inverted_index.modulates | 187 |
| abstract_inverted_index.patients. | 30 |
| abstract_inverted_index.treatment | 26, 129 |
| abstract_inverted_index.activities | 19, 45, 93, 119, 189 |
| abstract_inverted_index.associated | 184 |
| abstract_inverted_index.comparison | 121 |
| abstract_inverted_index.considered | 172 |
| abstract_inverted_index.difference | 101 |
| abstract_inverted_index.genotypes, | 166 |
| abstract_inverted_index.(1.81±0.93 | 59 |
| abstract_inverted_index.covariables | 158 |
| abstract_inverted_index.improvement | 146 |
| abstract_inverted_index.significant | 145 |
| abstract_inverted_index.transporter | 18 |
| abstract_inverted_index.(P>0.05). | 156 |
| abstract_inverted_index.(p<0.05). | 88 |
| abstract_inverted_index.2.68±0.87), | 61 |
| abstract_inverted_index.inflammatory | 161, 182 |
| abstract_inverted_index.intensifying | 25, 128 |
| abstract_inverted_index.participants | 39 |
| abstract_inverted_index.(0.089±0.037 | 90 |
| abstract_inverted_index.(0.154±0.085 | 106 |
| abstract_inverted_index.0.069±0.017) | 92 |
| abstract_inverted_index.significantly | 79 |
| abstract_inverted_index.statistically | 150 |
| abstract_inverted_index.0.136±0.065), | 108 |
| abstract_inverted_index.P-glycoprotein | 16 |
| abstract_inverted_index.administration | 49 |
| abstract_inverted_index.demographic-related | 169 |
| cited_by_percentile_year.max | 94 |
| cited_by_percentile_year.min | 89 |
| countries_distinct_count | 2 |
| institutions_distinct_count | 10 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.7799999713897705 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.51815403 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |